VPID-INFO
BOLETÍN INFORMATIVO SEMANAL
*Artículos *Patentes *Tablas de Contenido
Vicepresidencia de Investigación y Desarrollo (VPID)
FINLAY INSTITUTO

Editor: NOEL GONZÁLEZ GOTERA
Diseño: Lic. Roberto Chávez y Liuder Machado.
Foto: Lic. Belkis Romeu e Instituto Finlay

Número 068
Semana 260113 - 010213
La Habana, Cuba.

ARTÍCULOS CIENTÍFICOS

Publicaciones incluidas en *PubMED* durante el período comprendido entre el 26 de enero y el 1ro. de febrero de 2013. Con "vaccin*" en título: 76 artículos recuperados.

Vacunas meningococo (Neisseria meningitidis)

51. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults.

Marshall HS, Richmond PC, Nissen MD, Wouters A, Baber J, Jiang Q, Anderson AS, Jones TR, Harris SL, Jansen KU, Perez JL.

Vaccine. 2013 Jan 24. doi:pii: S0264-410X(13)00078-9. 10.1016/j.vaccine.2013.01.021. [Epub ahead of print]

PMID: 23352429
[PubMed - as supplied by publisher]

Related citations

72. One or Two Doses of Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine is Immunogenic in 9-12 Month Old Children.

Klein NP, Baine Y, Bianco V, Lestrate PR, Naz A, Blatter M, Friedland LR, Miller JM.

Pediatr Infect Dis J. 2013 Jan 23. [Epub ahead of print]

PMID: 23348814
[PubMed - as supplied by publisher]

Related citations

Vacunas BCG – ONCO BCG (Mycobacterium bovis)

Vacunas BCG – ONCO BCG (Mycobacterium bovis)

76. Distant lymph nodes serve as pools of Th1 cells induced by neonatal BCG vaccination for the prevention of asthma in mice.

Zhang G, Wang P, Qiu Z, Qin X, Lin X, Li N, Huang H, Liu H, Hua W, Chen Z, Zhao H, Li W, Shen H.

Allergy. 2013 Jan 25. doi: 10.1111/all.12099. [Epub ahead of print]

PMID: 23346957
[PubMed - as supplied by publisher]

Related citations

Vacunas neumococo (Streptococcus pneumoniae)

27. Association of infant pneumococcal vaccination with pneumococcal pneumonia among mothers: A nested case-control study using the GPRD.

Hak E, Shea KM, Jick SS.

Vaccine. 2013 Jan 25. doi:pii: S0264-410X(13)00075-3. 10.1016/j.vaccine.2013.01.018. [Epub ahead of print]

PMID: 23357195
[PubMed - as supplied by publisher]

Related citations

60. Sweet's syndrome triggered by pneumococcal vaccination.

Pedrosa AF, Morais P, Nogueira A, Pardal J, Azevedo F.

Cutan Ocul Toxicol. 2013 Jan 25. [Epub ahead of print]

PMID: 23351017
[PubMed - as supplied by publisher]

Related citations

71. Near Complete Elimination of the Seven Valent Pneumococcal Conjugate Vaccine Serotypes in Tennessee.

Halasa NB, Grijalva CG, Arbogast PG, Talbot TR, Craig AS, Griffin MR, Schaffner W.

Pediatr Infect Dis J. 2013 Jan 23. [Epub ahead of print]

PMID: 23348816
[PubMed - as supplied by publisher]

Related citations

Vacunas cólera (Vibrio cholerae)

2. Herd protection by a bivalent-killed-whole-cell oral cholera vaccine in the slums of Kolkata, India.

Ali M, Sur D, You YA, Kanungo S, Sah B, Manna B, Puri M, Wierzba TF, Donner A, Nair GB, Bhattacharya SK, Dhingra MS, Deen JL, Lopez AL, Clemens J.

Clin Infect Dis. 2013 Jan 29. [Epub ahead of print]

PMID: 23362293
[PubMed - as supplied by publisher]

Related citations

Vacunas, otras

1.

Attitudes Toward HPV Vaccination Among Low-Income and Minority Parents of Sons: A Qualitative Analysis.

Perkins RB, Tipton H, Shu E, Marquez C, Belizaire M, Porter C, Clark JA, Pierre-Joseph N.

Clin Pediatr (Phila). 2013 Jan 29. [Epub ahead of print]

PMID:
23362316
[PubMed - as supplied by publisher]

Related citations

2.

Herd protection by a bivalent-killed-whole-cell oral cholera vaccine in the slums of Kolkata, India.

Ali M, Sur D, You YA, Kanungo S, Sah B, Manna B, Puri M, Wierzba TF, Donner A, Nair GB, Bhattacharya SK, Dhingra MS, Deen JL, Lopez AL, Clemens J.

Clin Infect Dis. 2013 Jan 29. [Epub ahead of print]

PMID:
23362293
[PubMed - as supplied by publisher]

Related citations

3. Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland.

Hemming M, Räsänen S, Huhti L, Paloniemi M, Salminen M, Vesikari T.

Eur J Pediatr. 2013 Jan 30. [Epub ahead of print]

PMID:
23361964
[PubMed - as supplied by publisher]

Related citations

4.

Billing Practices of Local Health Departments Providing 2009 Pandemic Influenza A (H1N1) Vaccine.

Lindley MC.

J Public Health Manag Pract. 2013 Jan 28. [Epub ahead of print]

PMID:
23360957
[PubMed - as supplied by publisher]

Related citations

5.

Evaluation of an autogenous vaccine in cattle against Escherichia coli bearing the CTX-M-14 plasmid.

Reeves HE, Lotz SB, Kennedy E, Randall LP, Coldham NG, La Ragione RM.

Res Vet Sci. 2013 Jan 26. doi:pii: S0034-5288(13)00003-9. 10.1016/j.rvsc.2013.01.001. [Epub ahead of print]

PMID:
23360687
[PubMed - as supplied by publisher]

Related citations

6.

Comparing TCR Beta Chain variable Gene Profile Skewness between Children with Tuberculosis and BCG-vaccinated Children.

Zhou JW, Kong C, Luo J, Cao J, Shi Y.

Arch Iran Med. 2013 Feb;16(2):104-8. doi: 013162/AIM.0011.

PMID:
23360633
[PubMed - in process]

Related citations

7.

Impact of vaccination on admissions for Haemophilus influenzae b meningitis from 2004 to 2008 in Bobo Dioulasso, Burkina Faso.

Kaboré NF, Poda GE, Barro M, Cessouma R, Héma A, Ouedraogo AS, Sawadogo AB, Nacro B.

Med Sante Trop. 2013 Jan 30. [Epub ahead of print]

PMID:
23360620
[PubMed - as supplied by publisher]

Related citations

8.

How has the flu virus infected the Web? 2010 influenza and vaccine information available on the Internet.

Covolo L, Mascaretti S, Caruana A, Orizio G, Caimi L, Gelatti U.

BMC Public Health. 2013 Jan 29;13(1):83. [Epub ahead of print]

PMID:
23360311
[PubMed - as supplied by publisher]

Related citations

9.

Recombinant Salmonella Vaccination Technology and Its Application to Human Bacterial Pathogens.

Zhang S, Walters N, Cao L, Robison A, Yang X.

Curr Pharm Biotechnol. 2013 Jan 9. [Epub ahead of print]

PMID:
23360265
[PubMed - as supplied by publisher]

Related citations

10.

Phylogenetic Comparison of Influenza Virus Isolates from Three Medical Centers in Tehran with the Vaccine Strains during 2008-2009.

Mousavi SF, Kheiri MT, Hosseini SM, Taghizadeh M, Fotouhi F, Heydarchi B, Bashar R, Gomari H.

Iran J Med Sci. 2011 Sep;36(3):172-7.

PMID:
23359291
[PubMed]

Related citations

11.

Pfizer's men B vaccine shows promise in phase 2.

[No authors listed]

Hum Vaccin Immunother. 2012 Aug;8(8):1016-7. No abstract available.

PMID:
23359878
[PubMed - in process]

Related citations

12.

Study: shingles vaccine safe for patients on immune-suppressing drugs.

[No authors listed]

Hum Vaccin Immunother. 2012 Aug;8(8):1015-6. No abstract available.

PMID:
23359877
[PubMed - in process]

Related citations

13.

DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge.

Patel V, Jalah R, Kulkarni V, Valentin A, Rosati M, Alicea C, von Gegerfelt A, Huang W, Guan Y, Keele BF, Bess JW Jr, Piatak M Jr, Lifson JD, Williams WT, Shen X, Tomaras GD, Amara RR, Robinson HL, Johnson W, Broderick KE, Sardesai NY, Venzon DJ, Hirsch VM, Felber BK, Pavlakis GN.

Proc Natl Acad Sci U S A. 2013 Jan 28. [Epub ahead of print]

PMID:
23359688
[PubMed - as supplied by publisher]
Free Article

Related citations

14.

Coverage and Effectiveness of Kyasanur Forest Disease (KFD) Vaccine in Karnataka, South India, 2005-10.

Kasabi GS, Murhekar MV, Sandhya VK, Raghunandan R, Kiran SK, Channabasappa GH, Mehendale SM.

PLoS Negl Trop Dis. 2013 Jan;7(1):e2025. doi: 10.1371/journal.pntd.0002025. Epub 2013 Jan 24.

PMID:
23359421
[PubMed - in process]
Free Article

Related citations

15.

Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine.

Laheru D, Biedrzycki B, Jaffee EM.

Methods Mol Biol. 2013;980:175-203. doi: 10.1007/978-1-62703-287-2_9.

PMID:
23359154
[PubMed - in process]

Related citations

16.

[Herpes zoster after varicella-zoster vaccination.]

Fahlbusch M, Wesselmann U, Lehmann P.

Hautarzt. 2013 Jan 30. [Epub ahead of print] German.

PMID:
23358727
[PubMed - as supplied by publisher]

Related citations

17.

Inflammatory responses to hepatitis B virus vaccine in healthy term infants.

Celik IH, Demirel G, Canpolat FE, Erdeve O, Dilmen U.

Eur J Pediatr. 2013 Jan 29. [Epub ahead of print]

PMID:
23358708
[PubMed - as supplied by publisher]

Related citations

18.

Estimation of the Impact of a Japanese Encephalitis Immunization Program with Live, Attenuated SA 14-14-2 Vaccine in Nepal.

Upreti SR, Janusz K, Schluter WW, Bichha RP, Shakya G, Biggerstaff BJ, Shrestha MM, Sedai TR, Fischer M, Gibbons RV, Shrestha S, Hills SL.

Am J Trop Med Hyg. 2013 Jan 28. [Epub ahead of print]

PMID:
23358643
[PubMed - as supplied by publisher]
Free Article

Related citations

19.

The Bayesian Model on Human Papillomavirus Vaccination in Italy Lacks Transparency.

Garattini L, van de Vooren K.

Med Care. 2013 Jan 25. [Epub ahead of print] No abstract available.

PMID:
23358389
[PubMed - as supplied by publisher]

Related citations

20.

Influenza Vaccination and Its Association With Clinic Use of Evidence-Based Practices and Individual Patient Characteristics, San Diego County, 2009.

McAuliffe K, Peddecord KM, Wang W, Ralston K, Deguire M, Waters-Montijo K, Sawyer MH.

J Public Health Manag Pract. 2013 Mar;19(2):178-186.

PMID:
23358297
[PubMed - as supplied by publisher]

Related citations

Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine.

Adotevi O, Dosset M, Galaine J, Beziaud L, Godet Y, Borg C.

Hum Vaccin Immunother. 2013 Jan 28;9(5). [Epub ahead of print]

PMID:
23357860
[PubMed - as supplied by publisher]

Related citations

22.

Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies.

Jit M, Newall AT, Beutels P.

Hum Vaccin Immunother. 2013 Jan 28;9(5). [Epub ahead of print]

PMID:
23357859
[PubMed - as supplied by publisher]

Related citations

23.

Tolerogenic vaccines for Multiple sclerosis.

Mannie MD, Curtis AD.

Hum Vaccin Immunother. 2013 Jan 28;9(5). [Epub ahead of print]

PMID:
23357858
[PubMed - as supplied by publisher]

Related citations

24.

Immunogenicity, protective efficacy and safety of a recombinant DNA vaccine encoding truncated Plasmodium yoelii sporozoite asparagine-rich protein 1 (PySAP1).

Zhao J, Deng S, Liang J, Cao Y, Liu J, Du F, Shang H, Cui L, Luo E.

Hum Vaccin Immunother. 2013 Jan 28;9(5). [Epub ahead of print]

PMID:
23357857
[PubMed - as supplied by publisher]

Related citations

25.

No evidence for positive selection at two potential targets for malaria transmission-blocking vaccines in Anopheles gambiae s.s.

Crawford JE, Rottschaefer SM, Coulibaly B, Sacko M, Niaré O, Riehle MM, Traore SF, Vernick KD, Lazzaro BP.

Infect Genet Evol. 2013 Jan 25. doi:pii: S1567-1348(13)00023-3. 10.1016/j.meegid.2013.01.006. [Epub ahead of print]

PMID:
23357581
[PubMed - as supplied by publisher]

Related citations

26.

Strengthening vaccination policies in Latin America: An evidence-based approach.

Tapia-Conyer R, Betancourt-Cravioto M, Saucedo-Martínez R, Motta-Murguía L, Gallardo-Rincón H.

Vaccine. 2013 Jan 25. doi:pii: S0264-410X(12)01849-X. 10.1016/j.vaccine.2012.12.062. [Epub ahead of print]

PMID:
23357196
[PubMed - as supplied by publisher]

Related citations

27.

Association of infant pneumococcal vaccination with pneumococcal pneumonia among mothers: A nested case-control study using the GPRD.

Hak E, Shea KM, Jick SS.

Vaccine. 2013 Jan 25. doi:pii: S0264-410X(13)00075-3. 10.1016/j.vaccine.2013.01.018. [Epub ahead of print]

PMID:
23357195
[PubMed - as supplied by publisher]

Related citations

28.

Effects of vaccination against reproductive diseases on reproductive performance of lactating dairy cows submitted to AI.

Pereira MH, Cooke RF, Alfieri AA, Vasconcelos JL.

Anim Reprod Sci. 2013 Jan 10. doi:pii: S0378-4320(13)00004-3. 10.1016/j.anireprosci.2012.12.011. [Epub ahead of print]

PMID:
23357089
[PubMed - as supplied by publisher]

Related citations

29.

Development and evaluation of a replicon particle vaccine expressing the E2 glycoprotein of bovine viral diarrhea virus (BVDV) in cattle.

Loy JD, Gander J, Mogler M, Vander Veen R, Ridpath J, Harris DH, Kamrud K.

Virol J. 2013 Jan 28;10(1):35. [Epub ahead of print]

PMID:
23356714
[PubMed - as supplied by publisher]
Free Article

Related citations

30.

Interleukin-1beta receptor expressed by modified vaccinia virus Ankara interferes with interleukin-1beta activity produced in various virus-infected antigen-presenting cells.

Zimmerling S, Waibler Z, Resch T, Sutter G, Schwantes A.

Virol J. 2013 Jan 28;10(1):34. [Epub ahead of print]

PMID:
23356675
[PubMed - as supplied by publisher]

Free Article

Related citations

31.

[Guidance for vaccination in adult].

Niki Y, Oishi K, Kawakami K, Taniguchi K, Watanabe A, Watanabe H.

Nihon Naika Gakkai Zasshi. 2012 Dec 10;101(12):3585-97. Japanese. No abstract available.

PMID:
23356186
[PubMed - in process]

Related citations

32.

Low cost tuberculosis vaccine antigens in capsules: expression in chloroplasts, bio-encapsulation, stability and functional evaluation in vitro.

Lakshmi PS, Verma D, Yang X, Lloyd B, Daniell H.

PLoS One. 2013;8(1):e54708. doi: 10.1371/journal.pone.0054708. Epub 2013 Jan 23.

PMID:
23355891
[PubMed - in process]
Free Article

Related citations

33.

Correction: Key Steps in Developing a Cognitive Vaccine against Traumatic Flashbacks: Visuospatial Tetris versus Verbal Pub Quiz.

Holmes EA, James EL, Kilford EJ, Deeprose C.

PLoS One. 2012;7(11). doi: 10.1371/annotation/eba0a0c8-df20-496b-a184-29e30b8d74d0. Epub 2012 Nov 14.

PMID:
23355867
[PubMed - as supplied by publisher]
Free Article

Related citations

34.

Correction: A Cost Effectiveness and Capacity Analysis for the Introduction of Universal Rotavirus Vaccination in Kenya: Comparison between Rotarix and RotaTeq Vaccines.

van Hoek AJ, Ngama M, Ismail A, Chuma J, Cheburet S, Mutonga D, Kamau T, Nokes DJ.

PLoS One. 2012;7(11). doi: 10.1371/annotation/6b9d910e-4c85-41ca-ae56-b5996e81820a. Epub 2012 Nov 21.

PMID:
23355862
[PubMed - as supplied by publisher]
Free Article

Related citations

35.

Correction: Potential Role of Specific Antibodies as Important Vaccine Induced Protective Mechanism against Aeromonas salmonicida in Rainbow Trout.

Rømer Villumsen K, Dalsgaard I, Holten-Andersen L, Raida MK.

PLoS One. 2012;7(11). doi: 10.1371/annotation/48f605ab-75a9-4f93-9b4a-ab4358cd15d6. Epub 2012 Nov 14.

PMID:
23355858
[PubMed - as supplied by publisher]
Free Article

Related citations

36.

Vaccines and immunotherapy against fungi: the new frontier.

Nosanchuk JD, Taborda CP.

Front Microbiol. 2013;4:6. doi: 10.3389/fmicb.2013.00006. Epub 2013 Jan 25. No abstract available.

PMID:
23355835
[PubMed]
Free Article

Related citations

37.

Investigation of respiratory disease in IBR vaccinated dairy herds.

Penny CD.

Vet Rec. 2013 Jan 26;172(4):109-10. doi: 10.1136/vr.f468. No abstract available.

PMID:
23355716
[PubMed - in process]

Related citations

38.

Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer.

Huang YL, Hung JT, Cheung SK, Lee HY, Chu KC, Li ST, Lin YC, Ren CT, Cheng TJ, Hsu TL, Yu AL, Wu CY, Wong CH.

Proc Natl Acad Sci U S A. 2013 Jan 25. [Epub ahead of print]

PMID:
23355685
[PubMed - as supplied by publisher]

Related citations

39.

FUNDING HIV-VACCINE RESEARCH IN DEVELOPING COUNTRIES-WHAT IS WRONG WITH IAVI's RECOMMENDATION?

Sonntag D.

Health Econ. 2013 Jan 28. doi: 10.1002/hec.2909. [Epub ahead of print]

PMID:
23355491
[PubMed - as supplied by publisher]

Related citations

40.

A Vaccine against Streptococcus pyogenes : The Potential to Prevent Rheumatic Fever and Rheumatic Heart Disease.

Guilherme L, Ferreira FM, Köhler KF, Postol E, Kalil J.

Am J Cardiovasc Drugs. 2013 Jan 25. [Epub ahead of print]

PMID:
23355360
[PubMed - as supplied by publisher]

Related citations

Preventive misconception and adolescents' knowledge about HIV vaccine trials.

Ott MA, Alexander AB, Lally M, Steever JB, Zimet GD; the Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions.

J Med Ethics. 2013 Jan 25. [Epub ahead of print]

PMID:
23355050
[PubMed - as supplied by publisher]

Related citations

42.

A child with a long-standing, intensely itching subcutaneous nodule on a thigh: an uncommon (?) reaction to commonly used vaccines.

Bergfors E, Lundmark K, Nyström Kronander U.

BMJ Case Rep. 2013 Jan 24;2013. doi:pii: bcr2012007779. 10.1136/bcr-2012-007779.

PMID:
23354861
[PubMed - in process]

Related citations

43.

Rapid Vaccination Using an Acetalated Dextran Microparticulate Subunit Vaccine Confers Protection Against Triplicate Challenge by Bacillus Anthracis.

Schully KL, Sharma S, Peine KJ, Pesce J, Elberson MA, Fonseca ME, Prouty AM, Bell MG, Borteh H, Gallovic M, Bachelder EM, Keane-Myers A, Ainslie KM.

Pharm Res. 2013 Jan 25. [Epub ahead of print]

PMID:
23354770
[PubMed - as supplied by publisher]

Related citations

44.

Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinson's disease.

Chen Z, Yang Y, Yang X, Zhou C, Li F, Lei P, Zhong L, Jin X, Peng G.

Neurol Sci. 2013 Jan 25. [Epub ahead of print]

PMID:
23354599
[PubMed - as supplied by publisher]

Related citations

45.

Adult immunization policies in advanced economies: vaccination recommendations, financing, and vaccination coverage.

Wu LA, Kanitz E, Crumly J, D'Ancona F, Strikas RA.

Int J Public Health. 2013 Jan 25. [Epub ahead of print]

PMID:
23354183
[PubMed - as supplied by publisher]

Related citations

46.

Sero-epidemiology of hepatitis B markers in the population of Tuscany, Central Italy, 20 years after the implementation of universal vaccination.

Boccalini S, Pellegrino E, Tiscione E, Pesavento G, Bechini A, Levi M, Rapi S, Mercurio S, Mannelli F, Peruzzi M, Berardi C, Bonanni P.

Hum Vaccin Immunother. 2013 Jan 25;9(3). [Epub ahead of print]

PMID:
23354158
[PubMed - as supplied by publisher]

Related citations

47.

Development of a DNA-launched replicon as a vaccine for porcine reproductive and respiratory syndrome virus.

Pujhari S, Baig TT, Hansra S, Zakhartchouk AN.

Virus Res. 2013 Jan 23. doi:pii: S0168-1702(13)00012-9. 10.1016/j.virusres.2013.01.011. [Epub ahead of print]

PMID:
23353778
[PubMed - as supplied by publisher]

Related citations

48.

Polymer multilayer tattooing for enhanced DNA vaccination.

Demuth PC, Min Y, Huang B, Kramer JA, Miller AD, Barouch DH, Hammond PT, Irvine DJ.

Nat Mater. 2013 Jan 27. doi: 10.1038/nmat3550. [Epub ahead of print]

PMID:
23353628
[PubMed - as supplied by publisher]

Related citations

49.

Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial.

Zhu FC, Liang ZL, Li XL, Ge HM, Meng FY, Mao QY, Zhang YT, Hu YM, Zhang ZY, Li JX, Gao F, Chen QH, Zhu QY, Chu K, Wu X, Yao X, Guo HJ, Chen XQ, Liu P, Dong YY, Li FX, Shen XL, Wang JZ.

Lancet. 2013 Jan 23. doi:pii: S0140-6736(12)61764-4. 10.1016/S0140-6736(12)61764-4. [Epub ahead of print]

PMID:
23352749
[PubMed - as supplied by publisher]

Related citations

50.

Limitations of the study "Cost-effectiveness of tick-borne encephalitis vaccination in Slovenian adults"

Kos M, Locatelli I.

Vaccine. 2013 Jan 23. doi:pii: S0264-410X(12)01852-X. 10.1016/j.vaccine.2012.12.065. [Epub ahead of print] No abstract available.

PMID:
23352724
[PubMed - as supplied by publisher]

Related citations

51.

A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults.

Marshall HS, Richmond PC, Nissen MD, Wouters A, Baber J, Jiang Q, Anderson AS, Jones TR, Harris SL, Jansen KU, Perez JL.

Vaccine. 2013 Jan 24. doi:pii: S0264-410X(13)00078-9. 10.1016/j.vaccine.2013.01.021. [Epub ahead of print]

PMID:
23352429
[PubMed - as supplied by publisher]

Related citations

52.

Efficacy of a divalent and a multivalent water-in-oil formulated vaccine against a highly virulent strain of Flavobacterium psychrophilum after intramuscular challenge of rainbow trout (Oncorhynchus mykiss).

Fredriksen BN, Olsen RH, Furevik A, Souhoka RA, Gauthier D, Brudeseth B.

Vaccine. 2013 Jan 22. doi:pii: S0264-410X(13)00051-0. 10.1016/j.vaccine.2013.01.016. [Epub ahead of print]

PMID:
23352330
[PubMed - as supplied by publisher]

Related citations

53.

A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.

Gwinn WM, Johnson BT, Kirwan SM, Sobel AE, Abraham SN, Gunn MD, Staats HF.

Vaccine. 2013 Jan 22. doi:pii: S0264-410X(13)00034-0. 10.1016/j.vaccine.2013.01.012. [Epub ahead of print]

PMID:
23352329
[PubMed - as supplied by publisher]

Related citations

54.

Assessment of the vaccine industry in Iran in context of accession to WTO: a survey study.

Hashemi Meshkini A, Kebriaeezadeh A, Dinarvand R, Nikfar S, Habibzadeh M, Vazirian I.

Daru. 2012 Aug 30;20(1):19. doi: 10.1186/2008-2231-20-19.

PMID:
23351841
[PubMed - in process]

Related citations

55.

[The Janus face of monoclonal antibodies in oncology: passive immunity and vaccination].

Deligne C, Teillaud JL.

Med Sci (Paris). 2013 Jan;29(1):57-63. doi: 10.1051/medsci/2013291014. Epub 2013 Jan 25. French.

PMID:
23351695
[PubMed - in process]

Related citations

56.

[Towards a universal vaccine against flu?].

Dreyfus C.

Med Sci (Paris). 2013 Jan;29(1):22-5. doi: 10.1051/medsci/2013291007. Epub 2013 Jan 25. French. No abstract available.

PMID:
23351688
[PubMed - in process]

Related citations

57.

Short-term supplementation with active hexose correlated compound improves the antibody response to influenza B vaccine.

Roman BE, Beli E, Duriancik DM, Gardner EM.

Nutr Res. 2013 Jan;33(1):12-7. doi: 10.1016/j.nutres.2012.11.001. Epub 2012 Dec 4.

PMID:
23351405

[PubMed - in process]

Related citations

58.

IRES-based Venezuelan equine encephalitis vaccine candidate elicits protective immunity in mice.

Rossi SL, Guerbois M, Gorchakov R, Plante KS, Forrester NL, Weaver SC.

Virology. 2013 Jan 22. doi:pii: S0042-6822(12)00573-9. 10.1016/j.virol.2012.11.013. [Epub ahead of print]

PMID:
23351391
[PubMed - as supplied by publisher]

Related citations

59.

Pharmacokinetic Comparison of Acetaminophen Elixir Versus Suppositories in Vaccinated Infants (Aged 3 to 36 Months): A Single-Dose, Open-Label, Randomized, Parallel-Group Design.

Walson PD, Halvorsen M, Edge J, Casavant MJ, Kelley MT.

Clin Ther. 2013 Jan 22. doi:pii: S0149-2918(12)00733-3. 10.1016/j.clinthera.2012.12.016. [Epub ahead of print]

PMID:
23351277
[PubMed - as supplied by publisher]

Related citations

60.

Sweet's syndrome triggered by pneumococcal vaccination.

Pedrosa AF, Morais P, Nogueira A, Pardal J, Azevedo F.

Cutan Ocul Toxicol. 2013 Jan 25. [Epub ahead of print]

PMID:
23351017
[PubMed - as supplied by publisher]

Related citations

Pre-natal exposure to perfluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related health outcomes in early childhood.

Granum B, Haug LS, Namork E, Stølevik SB, Thomsen C, Aaberge IS, van Loveren H, Løvik M, Nygaard UC.

J Immunotoxicol. 2013 Jan 25. [Epub ahead of print]

PMID:
23350954
[PubMed - as supplied by publisher]

Related citations

62.

More than 1400 badgers vaccinated in Wales.

[No authors listed]

Vet Rec. 2012 Dec 8;171(23):578. doi: 10.1136/vr.e8179. No abstract available.

PMID:
23223459
[PubMed - indexed for MEDLINE]

Related citations

63.

Antigenicity and diagnostic potential of vaccine candidates in human chagas disease.

Gupta S, Wan X, Zago MP, Martinez Sellers VC, Silva TS, Assiah D, Dhiman M, Nuñez S, Petersen JR, Vázquez-Chagoyán JC, Estrada-Franco JG, Garg NJ.

PLoS Negl Trop Dis. 2013 Jan;7(1):e2018. doi: 10.1371/journal.pntd.0002018. Epub 2013 Jan 17.

PMID:
23350012
[PubMed - in process]
Free PMC Article

Related citations

64.

Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia ankara vaccines: a systematic review.

Elizaga ML, Vasan S, Marovich MA, Sato AH, Lawrence DN, Chaitman BR, Frey SE, Keefer MC; MVA Cardiac Safety Working Group.

PLoS One. 2013;8(1):e54407. doi: 10.1371/journal.pone.0054407. Epub 2013 Jan 17.

PMID:

23349878
[PubMed - in process]
Free PMC Article

Related citations

65.

A C-Repeat Binding Factor Transcriptional Activator (CBF/DREB1) from European Bilberry (Vaccinium myrtillus) Induces Freezing Tolerance When Expressed in Arabidopsis thaliana.

Oakenfull RJ, Baxter R, Knight MR.

PLoS One. 2013;8(1):e54119. doi: 10.1371/journal.pone.0054119. Epub 2013 Jan 17.

PMID:
23349799
[PubMed - in process]
Free PMC Article

Related citations

66.

Impact of rotavirus vaccination on hospitalisations in belgium: comparing model predictions with observed data.

Standaert B, Gomez JA, Raes M, Debrus S, Velázquez FR, Postma MJ.

PLoS One. 2013;8(1):e53864. doi: 10.1371/journal.pone.0053864. Epub 2013 Jan 18.

PMID:
23349754
[PubMed - in process]
Free PMC Article

Related citations

67.

Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial.

Zolla-Pazner S, Decamp AC, Cardozo T, Karasavvas N, Gottardo R, Williams C, Morris DE, Tomaras G, Rao M, Billings E, Berman P, Shen X, Andrews C, O'Connell RJ, Ngauy V, Nitayaphan S, de Souza M, Korber B, Koup R, Bailer RT, Mascola JR, Pinter A, Montefiori D, Haynes BF, Robb ML, Rerks-Ngarm S, Michael NL, Gilbert PB, Kim JH.

PLoS One. 2013;8(1):e53629. doi: 10.1371/journal.pone.0053629. Epub 2013 Jan 17.

PMID:
23349725
[PubMed - in process]

Free PMC Article

Related citations

68.

Comprehension of a simplified assent form in a vaccine trial for adolescents.

Lee S, Kapogiannis BG, Flynn PM, Rudy BJ, Bethel J, Ahmad S, Tucker D, Abdalian SE, Hoffman D, Wilson CM, Cunningham CK; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN).

J Med Ethics. 2013 Jan 24. [Epub ahead of print]

PMID:
23349510
[PubMed - as supplied by publisher]

Related citations

69.

Indirect Protection of Adults From Rotavirus by Pediatric Rotavirus Vaccination.

Anderson EJ, Shippee DB, Weinrobe MH, Davila MD, Katz BZ, Reddy S, Cuyugan MG, Lee SY, Simons YM, Yogev R, Noskin GA.

Clin Infect Dis. 2013 Jan 29. [Epub ahead of print]

PMID:
23349228
[PubMed - as supplied by publisher]

Related citations

70.

Max Bergmann lecture Protein epitope mimetics in the age of structural vaccinology.

Robinson JA.

J Pept Sci. 2013 Jan 24. doi: 10.1002/psc.2482. [Epub ahead of print]

PMID:
23349031
[PubMed - as supplied by publisher]

Related citations

71.

Near Complete Elimination of the Seven Valent Pneumococcal Conjugate Vaccine Serotypes in Tennessee.

Halasa NB, Grijalva CG, Arbogast PG, Talbot TR, Craig AS, Griffin MR, Schaffner W.

Pediatr Infect Dis J. 2013 Jan 23. [Epub ahead of print]

PMID:
23348816
[PubMed - as supplied by publisher]

Related citations

72.

One or Two Doses of Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine is Immunogenic in 9-12 Month Old Children.

Klein NP, Baine Y, Bianco V, Lestrate PR, Naz A, Blatter M, Friedland LR, Miller JM.

Pediatr Infect Dis J. 2013 Jan 23. [Epub ahead of print]

PMID:
23348814
[PubMed - as supplied by publisher]

Related citations

73.

Phase II Study of a Three-Dose Primary Vaccination Course of DTPa-IPV/Hib-MenC-TT Followed by a 12-Month Hib-MenC-TT Booster in Healthy Infants.

Khatami A, Snape MD, Ohene-Kena B, Young K, Oeser C, Michaelis LJ, Macleod E, Smee H, Van Der Meeren O, Leyssen M, Caubet M, Yu LM, Heath PT, Faust SN, Finn A, Pollard AJ.

Pediatr Infect Dis J. 2013 Jan 23. [Epub ahead of print]

PMID:
23348809
[PubMed - as supplied by publisher]

Related citations

74.

Phase 1 trial of recombinant Modified Vaccinia Ankara (MVA) encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients.

Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, Wong W, Wilson S, Johnson BF, Edwards C, Stocken DD, Rickinson AB, Steven NM, Chan AT.

Cancer Res. 2013 Jan 24. [Epub ahead of print]

PMID:

23348421
[PubMed - as supplied by publisher]

Related citations

75.

Parental refusal of vaccination and transplantation listing decisions: A nationwide survey.

Ladd JM, Karkazis K, Magnus D.

Pediatr Transplant. 2013 Jan 24. doi: 10.1111/petr.12046. [Epub ahead of print]

PMID:
23347536
[PubMed - as supplied by publisher]

Related citations

76.

Distant lymph nodes serve as pools of Th1 cells induced by neonatal BCG vaccination for the prevention of asthma in mice.

Zhang G, Wang P, Qiu Z, Qin X, Lin X, Li N, Huang H, Liu H, Hua W, Chen Z, Zhao H, Li W, Shen H.

Allergy. 2013 Jan 25. doi: 10.1111/all.12099. [Epub ahead of print]

PMID:
23346957
[PubMed - as supplied by publisher]

Related citations

PATENTES

United States Patent and Trademark Office (USPTO)

Estrategia de búsqueda "vaccine" en título y abstract

(ABST/vaccine AND ISD/20130123->20130201): 6 patentes recuperadas.

Vacunas BCG – ONCO BCG (Mycobacterium bovis)

3 8,361,482 Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease

Vacunas, otras

PAT. NO. **Title**

1 8,361,776 Adaptation of Pitman Moore strain of rabies virus to primary chick embryo fibroblast cell cultures

2 8,361,483 Epinecidin-1 as a vaccine adjuvant for enhancing immune responses

3 8,361,482 Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease

4 8,361,480 Attenuated ehrlichiosis vaccine

5 8,361,476 Vaccine composition comprising an antigen and a peptide having adjuvant properties

6 8,361,026 Apparatus and methods for self-administration of vaccines and other medicaments

European Patent Office (EPO)

Acumulado entre el 23 de enero y el 1ro. de febrero de 2013: 24 patentes recuperadas.

Vacuna tuberculosis (Mycobacterium tuberculosis)

12. Tuberculosis Vaccine

Publication info: ***US2013022638 (A1) 2013-01-24***

Vacuna tosferina (Bordetella pertussis)

Adyuvantes

7. BACTERIAL RNAS AS VACCINE ADJUVANTS

Publication info: *WO2013012875 (A2) 2013-01-24 8.*

Vacunas, otras

1. LIVE VACCINE FOR AVIARY DISEASES

Publication info:

EP2550015 (A1) 2013-01-30 2. USE OF PCSK9 AS A VACCINE FOR LOWERING CHOLESTEROL

Publication info:

EP2550011 (A1) 2013-01-30 3. Universal influenza vaccine based on recombinant modified vaccinia Ankara virus (MVA)

Publication info:

EP2550974 (A2) 2013-01-30 4. Method of Treating Patients with a Mucinous Glycoprotein (MUC-1) Vaccine

Publication info:

AU2012268892 (A1) 2013-01-24 5. Mycoplasma hyopneumoniae avirulent-adjuvanted live vaccine

Publication info:

AU2012261741 (A1) 2013-01-24 6. Vaccine and methods to reduce Campylobacter infection

Publication info:

AU2011264772 (A1) 2013-01-24 7. BACTERIAL RNAS AS VACCINE ADJUVANTS

Publication info:

WO2013012875 (A2) 2013-01-24 8. GEL VACCINE DELIVERY SYSTEM FOR TREATING POULTRY

Publication info:

WO2013012683 (A2) 2013-01-24 9. RECOMBINANT FELINE LEUKEMIA VIRUS VACCINE CONTAINING OPTIMIZED FELINE LEUKEMIA VIRUS ENVELOPE GENE

Publication info:

WO2013012446 (A1) 2013-01-24 10. MUTANT CANINE MADNESS VIRUS AND VACCINE

Publication info:

WO2013011942 (A1) 2013-01-24 11. ATTENUATED PLASMODIUM WITH DEACTIVATED HMGB2 GENE, AS VACCINE

Publication info:

WO2013011247 (A1) 2013-01-24 12. Tuberculosis Vaccine

Publication info:

US2013022638 (A1) 2013-01-24 13. RECOMBINANT BACULOVIRUS VACCINE

Publication info:

US2013022637 (A1) 2013-01-24 14. VACCINE FOR CHIKUNGUNYA VIRUS INFECTION

Publication info:

US2013022631 (A1) 2013-01-24 15. Novel neutralizing immunogen (NIMIV) of Rhinovirus and its use for vaccine applications

Publication info:

EP2548573 (A1) 2013-01-23 16. ADJUVANTED TOLEROGENS AS A MALARIA VACCINE

Publication info:

EP2548572 (A2) 2013-01-23 17. LIVE ATTENUATED CHIMERIC PORCINE CIRCOVIRUS VACCINE

Publication info:

EP2547770 (A2) 2013-01-23 18. BACTERIAL VACCINE COMPONENTS FROM STAPHYLOCOCCUS AUREUS AND USES THEREOF

Publication info:

EP2547361 (A1) 2013-01-23 19. DISRUPTED ADENOVIRUS-BASED VACCINE AGAINST DRUGS OF ABUSE

Publication info:

EP2547362 (A1) 2013-01-23 20. PEPTIDES, CONJUGATES AND METHOD FOR INCREASING IMMUNOGENICITY OF A VACCINE

Publication info:

EP2547364 (A1) 2013-01-23 21. COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GASTRIC CANCER AND OTHER CANCERS

Publication info:

EP2547691 (A1) 2013-01-23

TABLAS DE CONTENIDO

Revista Vaccine

New Articles in Press (21 January – 27 January, 2013)

1. **Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans** Original Research Article

   Available online 25 January 2013
   Wendy Peters, Jennifer R. Brandl, Jonathan D. Lindbloom, C. Josefina Martinez, Ciaran D. Scallan, George R. Trager, Debora W. Tingley, Martin L. Kabongo, Sean N. Tucker

   Highlights

   ► Oral immunization with rAd elicits γ-IFN and granzyme B producing T cells in humans ► Granzyme B responses can be boosted with oral immunization ► Oral immunization with rAd has a positive safety profile ► Oral immunization with rAd does not elicit substantial anti-vector antibody responses.

2. **Association of infant pneumococcal vaccination with pneumococcal pneumonia among mothers: A nested case–control study using the GPRD** Original Research Article

   Available online 25 January 2013
   Eelko Hak, Kimberly M. Shea, Susan S. Jick

   Highlights

   ► After PCV7 implementation in the UK, pneumococcal pneumonia in mothers increased. ► By 24 months of age, 35% of infants had incomplete PCV7-series in 2010. ► Pneumococcal pneumonia in mothers was associated with their infants PCV7 status.

3. **Immunization with recombinant subolesin does not reduce tick infection with tick-borne encephalitis virus nor protect mice against disease** Original Research Article

   Available online 25 January 2013
   Sabína Havlíková, Martina Ličková, Nieves Ayllón, Ladislav Roller, Mária Kazimírová, Mirko Slovák, Juan A. Moreno-Cid, José M. Pérez de la Lastra, Boris Klempa, José de la Fuente

   Highlights

► Subolesin expression is downregulated duringIxodes ricinustick feeding. ► Subolesin is induced in ticks infected with TBEV. ► Vaccination with subolesin reduced gene mRNA levels in nymphs. ► Subolesin vaccination did not reduce tick infection and transmission of TBEV.

4. **Strengthening vaccination policies in Latin America: An evidence-based approach** Review Article

Available online 25 January 2013
Roberto Tapia-Conyer, Miguel Betancourt-Cravioto, Rodrigo Saucedo-Martínez, Lourdes Motta-Murguía, Héctor Gallardo-Rincón

Highlights

► Recommendations for reducing vaccination inequality in Latin America include. ► Harmonising data collection, surveillance and immunisation schedules. ► New training programmes to support sustainable immunisation schemes. ► Innovative financing to provide solutions to the rising cost of vaccines. ► A common regulatory framework to facilitate vaccine registration. ► Public–private partnerships to provide regional investment for R&D.

5. **A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults** Original Research Article

Available online 24 January 2013
Helen S. Marshall, Peter C. Richmond, Michael D. Nissen, Ann Wouters, James Baber, Qin Jiang, Annaliesa S. Anderson, Thomas R. Jones, Shannon L. Harris, Kathrin U. Jansen, John L. Perez

Highlights

► First study of the final formulation of a bivalent rLP2086 vaccine in young adults. ► The vaccine was well tolerated; most AEs were not unusual for a vaccine trial. ► Most participants achieved hSBA titres≥1:4 against a panel of MnB target strains. ► hSBA MnB strains expressed diverse fHBP variants and suggest broad vaccine coverage. ► Data support further clinical development of the bivalent rLP2086 vaccine.

6. **Limitations of the study "Cost-effectiveness of tick-borne encephalitis vaccination in Slovenian adults"**

Available online 23 January 2013
Mitja Kos, Igor Locatelli

7. **A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen** Original Research Article

Available online 23 January 2013
William M. Gwinn, Brandi T. Johnson, Shaun M. Kirwan, Ashley E. Sobel, Soman N. Abraham, Michael D. Gunn, Herman F. Staats

Highlights

► Non-toxin adjuvants were compared to cholera toxin for nasal adjuvant activity. ► Adjuvant-dependent innate and adaptive cytokine responses were monitored as biomarkers of adjuvant activity. ► Non-toxin adjuvants were as effective as cholera toxin when used as nasal adjuvants. ► Each adjuvant exhibited a unique biomarker signature.

8. **Efficacy of a divalent and a multivalent water-in-oil formulated vaccine against a highly virulent strain of *Flavobacterium psychrophilum* after intramuscular challenge of rainbow trout (*Oncorhynchus mykiss*)** Original Research Article

Available online 23 January 2013
Børge N. Fredriksen, Rolf H. Olsen, Anette Furevik, Rachmilla A. Souhoka, David Gauthier, Bjørn Brudeseth

Highlights

► Vaccination with divalent and multivalent vaccines against BCWD. ► Intramuscular challenge with highly virulent Norwegian field strain ofFlavobacterium psychrophilum. ► High antibody responses in vaccinated groups. ► Reduced ulceration rates in vaccinated groups. ► Increased survival rates in vaccinated groups.

9. **Vaccination of feedlot cattle with extracts and membrane fractions from two *Mycoplasma bovis* isolates results in strong humoral immune responses but does not protect against an experimental challenge** Original Research Article

Available online 19 January 2013
Musa Mulongo, Tracy Prysliak, Jose Perez-Casal

Highlights

► Cattle were vaccinated withMycoplasma bovisextracts and membrane fractions formulated with CpG-ODN 2007. ► Significant IgG1 and IgG2 responses against extracts but only IgG1 responses against fractions were observed. ► There were no differences in clinical signs between the groups. ► The vaccines did not offer protection against an experimental challenge. ► Non-vaccinated animals challenged withM. bovismounted IgG1 and IgG2 responses against the bacterium.

Tabla de Contenidos. Volume 31, Issue 7, Pages 1009 - 1134, (4 February, 2013)

1. **Editorial Board/Aims and Scope**

Pages CO2

Short communication

2. **Oral vaccination with an adenovirus-vectored vaccine protects against botulism**

   Pages 1009-1011
   Shan Chen, Qingfu Xu, Mingtao Zeng

   Highlights

   ► An oral vaccine can elicit neutralizing antibody response against botulinum neurotoxin. ► The candidate oral vaccine can protect against lethal challenge with botulinum neurotoxin. ► The protective immunity against botulinum neurotoxin is vaccine dose dependent.

Regular papers

3. **Cell recruitment and antigen trafficking in afferent lymph after injection of antigen and poly(I:C) containing liposomes, in aqueous or oil-based formulations** Original Research Article

   Pages 1012-1018
   Michael de Veer, Melanie Neeland, Melissa Burke, Jill Pleasance, Jackie Nathanielsz, Martin Elhay, Els Meeusen

   Highlights

   ► Antigen is transported first by neutrophils and monocytes, then by dendritic cells. ► There is little antigen traffickingviaafferent lymph with oil-based formulations. ► Poly(I:C)-containing liposomes-in oil form ectopic lymphoid tissues.

4. **Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine** Original Research Article

   Pages 1019-1025
   Irina Tretyakova, Igor S. Lukashevich, Pamela Glass, Eryu Wang, Scott Weaver, Peter Pushko

   Highlights

   ► Novel iDNA platform was used for vaccination against VEEV alphavirus. ► Less than

10ng of pTC83 iDNA initiated replication of the vaccine virusin vitro. ► BALB/c mice vaccinated with a single dose of pTC83 iDNA have seroconverted. ► After challenge with VEEV, all pTC-83-vaccinated mice were protected. ► Proposed platform allows conversion of live attenuated virus into DNA vaccine.

5. **Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery** Original Research Article

Pages 1026-1033
Joel Meyer, Stephanie A. Harris, Iman Satti, Ian D. Poulton, Hazel C. Poyntz, Rachel Tanner, Rosalind Rowland, Kristin L. Griffiths, Helen A. Fletcher, Helen McShane

Highlights

► Candidate TB vaccine MVA85A is well tolerated intramuscularly or intradermally. ► Both routes are highly immunogenic. ► MVA85A-induced CD4+ T cell cytokine production was similar between the two routes.

6. **Method for the simultaneous assay of the different poliovirus types using surface plasmon resonance technology** Original Research Article

Pages 1034-1039
Catherine Manin, Sophie Naville, Marine Gueugnon, Monique Dupuy, Y. Bravo de Alba, Olivier Adam

Highlights

► Very tight binding of monoclonal antibodies to different polio virus types. ► SPR-based analytical method to assay simultaneously different virus types in mixtures. ► Method characterised by robustness, rapidity and linearity of response. ► Method suitable for vaccine production in-process analysis and final product quantification.

7. **Long-term response rates of successful hepatitis B vaccination in HIV-infected patients** Original Research Article

Pages 1040-1044
Vania Baptista Lopes, Robert J. Hassing, Theodora E.M.S. de Vries-Sluijs, Abdel el Barzouhi, Bettina E. Hansen, Martin Schutten, Robert A. de Man, Marchina E. van der Ende

Highlights

► We evaluated durability of anti-HBs titers after vaccination in HIV-infected adults. ► The durability of anti-HBs related to the anti-HBs after the primary vaccination. ► Mean time to loss of anti-HBs was 2 years for pts with anti-HBs 10–100IU/I. ► Mean time to loss of anti-HBs was 4.4 years for pts with anti-HBs >1000IU/I. ► HIV-RNA <50 and use of HAART were not associated durability of anti-HBs.

8. **Domestic goose as a model for West Nile virus vaccine efficacy** Original Research Article

Pages 1045-1050
Mariana Sá e Silva, Angela Ellis, Kemal Karaca, Jules Minke, Robert Nordgren, Shixuan Wu, David E. Swayne

Highlights

► We used domestic goose as vaccine efficacy model for WNV. ► Fowlpox vectored vaccine with WNV prM and E proteins provided the best protection. ► Domestic geese can be used in an efficacy model for vaccine protection studies. ► Parameters for protection include clinical, plasma titers, brain histopathological.

9. **Knowledge and awareness of HPV and the HPV vaccine among young women in the first routinely vaccinated cohort in England** Original Research Article

Pages 1051-1056
Harriet L. Bowyer, Laura A.V. Marlow, Sam Hibbitts, Kevin G. Pollock, Jo Waller

Highlights

► Little is known about HPV knowledge in vaccinated cohorts of girls in the UK. ► We surveyed girls in the first vaccinated cohort, three years after vaccination. ► Knowledge was low, with a fifth unaware of HPV. ► Many girls were unaware of the link between HPV infection and cervical cancer, and the need for cervical screening post-vaccination. ► There will be a need for targeted information when this cohort reaches screening age.

10. **Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against *Mycobacterium tuberculosis*** Original Research Article

Pages 1057-1064
Ying Waeckerle-Men, Nicolas Bruffaerts, Yuan Liang, Fabienne Jurion, Peter Sander, Thomas M. Kündig, Kris Huygen, Pål Johansen

Highlights

► Subcutaneous and intralymphatic vaccination withM. bovisBCG was compared in mice. ► Intralymphatic BCG administration produced strong CD4 and CD8 T-cell responses with TNF-α, IL-2, IL-17 and IFN-γ secretion. ► Protection against tuberculosis was obtained with very low BCG doses (2×103CFU). ► We demonstrate that efficient targeting to lymph nodes may help to overcome the efficacy problems of vaccination with BCG.

11. **Preclinical safety and immunogenicity evaluation of a nonavalent PorA native**

outer membrane vesicle vaccine against serogroup B meningococcal disease Original Research Article

Pages 1065-1071
Patricia Kaaijk, Ineke van Straaten, Bas van de Waterbeemd, Elmieke P.J. Boot, Lonneke M.A.R. Levels, Harry H. van Dijken, Germie P.J.M. van den Dobbelsteen

Highlights

► NonaMen has the potential to broadly protect against MenB disease. ► Nonamen was considered effective and safe in rabbits and mice. ► Risks-benefit balance favors use of plain NonaMen without an aluminium adjuvant.

12. **Nanoemulsion nasal adjuvant W805EC induces dendritic cell engulfment of antigen-primed epithelial cells** Original Research Article

Pages 1072-1079
Andrzej Myc, Jolanta F. Kukowska-Latallo, Douglas M. Smith, Crystal Passmore, Tiffany Pham, Pamela Wong, Anna U. Bielinska, James R. Baker

Highlights

► Facilitates antigen uptake by epithelial and dendritic cells. ► Promotes engulfment of epithelial by dendritic cells. ► Augments antigen transfer from epithelial to dendritic cells. ► Induces maturation of dendritic cells. ► Contributes to cell cycle arrest and apoptosis.

13. **Secular trends in diagnostic code density in electronic healthcare data from health care systems in the Vaccine Safety Datalink Project** Original Research Article

Pages 1080-1085
Rulin C. Hechter, Lei Qian, Lina S. Sy, Sharon K. Greene, Eric S. Weintraub, Allison L. Naleway, Ali Rowhani-Rahbar, James G. Donahue, Matthew F. Daley, Gabriela Vazquez-Benitez, Marlene M. Lugg, Steven J. Jacobsen

Highlights

► We assessed the secular trends in diagnostic code density during 2001–2009. ► An increasing trend in diagnostic code density was observed across all sites. ► Sudden changes were observed when changes in coding policies or data inclusion criteria took place. ► Inappropriate historical comparator may introduce a false positive association between a vaccine and an adverse event. ► Ongoing monitoring of the diagnostic code density may provide guidance on choice of study design and comparison groups.

14. **Environmental effects on protection against *Mycobacterium tuberculosis* after immunization with Ad85A** Original Research Article

Pages 1086-1093
Peter Beverley, Edward Ronan, Lianni Lee, Isabelle Arnold, Beatrice Bolinger, Fiona Powrie, Elma Tchilian

Highlights

► The environment alters the immune response to an intradermal (i.d.) TB subunit vaccine, Ad85A. ► Ad85A i.d. induces a lung immune response but is less protective againstMtbthan intranasal Ad85A. ► Oral administration of environmental mycobacteria reduces Ad85A i.d induced protection. ►In vivodepletion of CD25+ regulatory T cells abolishes the effect of oral mycobacteria.

15. **Safety and protective efficacy of live attenuated *Salmonella* Gallinarum mutants in Rhode Island Red chickens** Original Research Article

Pages 1094-1099
Arindam Mitra, Amanda Loh, Amanda Gonzales, Paweł Łaniewski, Crystal Willingham, Roy Curtiss III, Kenneth L. Roland

Highlights

► We developed an oral infection model of fowl typhoid. ► Constructed several reversibly rough mutants inS. Gallinarum. ► Constructed a regulated delayedcrpmutant. ► Developed health scoring system for assessing health of birds.

16. **A phase I clinical trial of a new 5-valent rotavirus vaccine** Original Research Article

Pages 1100-1105
Expedito J.A. Luna, Neuza M. Frazatti-Gallina, Maria C.S.T. Timenetsky, Maria R.A. Cardoso, Maria A.S.M. Veras, João L. Miraglia, Ana M.U. Escobar, Sandra J.F.E. Grisi, Isaias Raw, Alexander R. Precioso

Highlights

► A new 5-valent rotavirus vaccine has been evaluated in a double-blind phase 1 trial. ► No severe adverse events were observed. ► There was no significant difference in the frequency of AE between vaccine and control groups. ► The proportion of seroconversion was larger in the vaccine group for all five serotypes. ► Antibody levels were significantly higher in the vaccine group in comparison to the placebo group.

17. **Higher cross-subtype IFN-γ ELISpot responses to Gag and Nef peptides in Brazilian HIV-1 subtype B- and F1- than in C-infected subjects** Original Research Article

Pages 1106-1112
Fernanda Heloise Côrtes, Gonzalo Bello, Carla Vorsatz, José Henrique Pilotto, Monick Lindenmeyer Guimarães, Beatriz Grinsztejn, Valdiléa Gonçalves Veloso, Aguinaldo

Roberto Pinto, Mariza Gonçalves Morgado

Highlights

► Isolate sequence most similar to consensus is a useful strategy to immunogen design. ► Subtype B and F1 present a high cross-reactivity T cell response. ► Subtype F1 infected subjects presented higher responses than B- and C-infected subjects.

18. **Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control *Neisseria meningitidis* capsular group X outbreaks in Africa?** Original Research Article

Pages 1113-1116
Eva Hong, Marzia Monica Giuliani, Ala-Eddine Deghmane, Maurizio Comanducci, Brunella Brunelli, Peter Dull, Mariagrazia Pizza, Muhamed-Kheir Taha

Highlights

► A new recombinant vaccine against meningococci group B is under registration. ► We examined coverage of group X isolates emerging in Africa (no available vaccine). ► Vaccine components are conserved and expressed in African serogroup X isolates. ► Sera from vaccinated subjects killed effectively serogroup X isolates. ► The vaccine can further be investigated to control serogroup X outbreaks.

19. **Cost of hospitalizing children with invasive pneumococcal pneumonia** Original Research Article

Pages 1117-1122
Pedro Brotons, Gemma Gelabert, Cristian Launes, Elisa Sicuri, Roman Pallares, Carmen Muñoz-Almagro

Highlights

► We assess the hospital cost of children with invasive pneumococcal pneumonia. ► Non-PCV7 serotypes were associated with a high cost of disease. ► Complications, intensive care and surgical procedures determine higher costs. ► Hospital costs could be mitigated with PCV13 universal childhood vaccination.

20. **Association of HLA class II genes with clinical hyporesponsiveness to trivalent inactivated influenza vaccine in children** Original Research Article

Pages 1123-1128
Komal J. Narwaney, Jason M. Glanz, Jill M. Norris, Tasha E. Fingerlin, John E. Hokanson, Marian Rewers, Simon J. Hambidge

Highlights

► We examined if HLA genes are associated with clinical hyporesponsivness after TIV.

► Clinical hyporesponsiveness was occurrence of influenza illness in vaccinated children. ► HLA-DR7/4,DQB1*0302 was significant in non-Hispanic white children. ► HLA-DRB1*15 or 16 and HLA-DR7/Y were significant in Hispanic children. ► HLA class II genes are associated with clinical hyporesponsiveness to TIV.

21. **Population-based evaluation of type-specific HPV prevalence among women in British Columbia, Canada** Original Research Article

Pages 1129-1133
G.S. Ogilvie, D.A. Cook, D.L. Taylor, C. Rank, L. Kan, A. Yu, W. Mei, D.J. van Niekerk, A.J. Coldman, M. Krajden

Highlights

► 12.2% of women in a Canadian cervical cancer screening program are hrHPV positive. ► Highest rate in 20–24-year old women. ► HPV 16 was most prevalent sub-type. ► Agreement using three commercial genotyping methods for HPV 16 and 18 was high.

Tabla de Contenidos. Volume 31, Issue 5, Pages 725 - 856, 21 January, 2013)

1. **Editorial Board/Aims and Scope**

Pages CO2

Editorial

2. **Next generation personalized animals as an enabling technology in personalized vaccinology**

Pages 725-727
Gregory A. Poland, Oleg Mirochnitchenko

WHO article

3. **Global production capacity of seasonal influenza vaccine in 2011** Original Research Article

Pages 728-731
Jeffrey Partridge, Marie Paule Kieny

Highlights

► Influenza vaccines effectively reduce the impact of seasonal epidemics and pandemics. ► Higher demand for seasonal influenza vaccine is essential for pandemic preparedness. ► We compared 2011 global capacity and actual production with 2009 data. ► Global production capacity increased by 62% while actual production by only 8%. ► Major geographic imbalances in production and access to vaccine remain.

Short communication

4. **A campaign to increase the vaccination rate in a highly endemic tick-borne encephalitis region of Slovenia**

   Pages 732-734
   Irena Grmek Košnik, Andreja Krt Lah

   Highlights

   ► Incidence of tick-borne encephalitis (TBE) in Gorenjska region (Slovenia) is 30/100,000. ► The number of subjects protected by vaccination is only 6.8% of the population of Gorenjska. ► Charity activities to reduce the price of vaccination increase the vaccination rate.

Review

5. **Micro/nanoparticle adjuvants for antileishmanial vaccines: Present and future trends** Review Article

   Pages 735-749
   Ali Badiee, Vahid Heravi Shargh, Ali Khamesipour, Mahmoud Reza Jaafari

   Highlights

   ► A suitable adjuvant is needed to improve the efficacy of antileishmanial vaccines. ► Particulate adjuvants are the valuable strategy to enhance vaccine efficacies. ► The most challenging issue in the field of particulate adjuvants is their size. ► Liposomes plus immunostimulatory adjuvants are prospective antileishmanial vaccines.

Regular papers

6. **Correlates of high vaccination exemption rates among kindergartens** Original

Research Article

Pages 750-756
Michael S. Birnbaum, Elizabeth T. Jacobs, Jennifer Ralston-King, Kacey C. Ernst

Highlights

► We model the correlates of schools with increased vaccine exemption rates. ► Proportion of white students is associated with increased vaccine exemption rate. ► Defined local and statewide hotspots for were identified exemptions across Arizona. ► Local and statewide pockets warrant attention from all healthcare professionals.

7. **Coverage from Ontario, Canada's school-based HPV vaccine program: The first three years** Original Research Article

Pages 757-762
Sarah E. Wilson, Tara Harris, Pam Sethi, Jill Fediurek, Liane Macdonald, Shelley L. Deeks

Highlights

► Ontario, Canada implemented a school-based HPV vaccination program in 2007. ► We surveyed Ontario Public Health Units to obtain vaccine coverage information. ► Provincial coverage estimates were: 51% (year 1), 58% (year 2), 59% (year 3). ► There was large variation in coverage by Public Health Unit. ► Ontario's coverage is lower than many other jurisdictions with school programs.

8. **Knowledge of human papillomavirus (HPV) and HPV vaccination: An international comparison** Original Research Article

Pages 763-769
Laura A.V. Marlow, Gregory D. Zimet, Kirsten J. McCaffery, Remo Ostini, Jo Waller

9. **Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults** Original Research Article

Pages 770-776
David P. Greenberg, Corwin A. Robertson, Michael J. Noss, Mark M. Blatter, Rex Biedenbender, Michael D. Decker

Highlights

► Two distinct lineages of influenza B virus co-circulate annually. ► The B lineage chosen for TIV is often not the B lineage that circulates. ► QIV contains two influenza B strains, one from each lineage. ► QIV was as safe and immunogenic as licensed TIV in adults. ► QIV should offer protection against both B lineages simultaneously.

10. **Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants** Original Research Article

Pages 777-783
Shabir A. Madhi, Alane Izu, Avye Violari, Mark F. Cotton, Ravindre Panchia, Els Dobbels, Poonam Sewraj, Nadia van Niekerk, Patrick Jean-Philippe, Peter V. Adrian

Highlights

► Infants born to HIV+ mothers have low pneumococcal antibody levels. ► Immune response following two PCV doses in HIV+ is similar to HIV-infants. ► Three PCV doses are required for good immune responses to serotype 6B and 23F. ► A 2 dose PCV primary-series may result in an immunity-gap during early infancy.

11. **Enhancement of immune response to a DNA vaccine against *Mycobacterium tuberculosis* Ag85B by incorporation of an autophagy inducing system** Original Research Article

Pages 784-790
Jomkhwan Meerak, Supason P. Wanichwecharungruang, Tanapat Palaga

Highlights

► Kinase defective mTOR induces autophagy. ► Chitosan nanoparticles effectively delivers DNA vaccine containingMycobacterium tuberculosisAg85B and autophagy inducing plasmid. ► DNA vaccine incorporating kinase defective mTOR increases Th1 immune response against Ag85B.

12. **Antibody responses correlate with antigen dose and *in vivo* protection for oil-adjuvanted, experimental furunculosis (*Aeromonas salmonicida* subsp. salmonicida) vaccines in Atlantic salmon (*Salmo salar* L.) and can be used for batch potency testing of vaccines** Original Research Article

Pages 791-796
Anne Berit Romstad, Liv Jorun Reitan, Paul Midtlyng, Kjersti Gravningen, Øystein Evensen

Highlights

► Antibody response correlates close with antigen dose forA. salmonicidavaccines. ► There is a correlation between antibody response and protection against challenge. ► The ELISA method identified sub-potent vaccines better than challenge assays.

13. **Systematic annotation and analysis of "virmugens"—Virulence factors whose mutants can be used as live attenuated vaccines** Original Research Article

Pages 797-805
Rebecca Racz, Monica Chung, Zuoshuang Xiang, Yongqun He

Highlights

► On virmugens, virulence factors whose mutants are used as live attenuated vaccines. ► Curation and analysis of bacterial, viral, and protozoan virmugens. ► Specific virmugen patterns are identified. ► Host genes specifically induced by virmugen vaccines are annotated. ► A web-based virmugen database is developed for query and analysis.

14. **Tandem repeats of the extracellular domain of Matrix 2 influenza protein exposed in *Brucella* lumazine synthase decameric carrier molecule induce protection in mice** Original Research Article

Pages 806-812
Paula Alvarez, Vanesa Zylberman, Giselle Ghersi, Lorena Boado, Carlos Palacios, Fernando Goldbaum, Nora Mattion

Highlights

► The ectodomain of the Matrix 2 protein (M2e) is nearly invariant in all human influenza A strains. ► Influenza M2e peptide fused toBrucellaspp. lumazine synthase protein is remarkably stable. ► The chimera may expose 10–40 M2e copies in each subunit with the expected decameric conformation. ► Mice immunized with a multicopy chimera were protected from challenge with live influenza virus.

15. **Development and pre-clinical assessment of a 73 kD chimeric fusion protein as a defined sub-unit vaccine for leprosy** Original Research Article

Pages 813-819
Malcolm S. Duthie, Lucas H. Sampaio, Regiane M. Oliveira, Vanitha S. Raman, Joanne O'Donnell, H. Remy Bailor, Greg C. Ireton, Ana Lucia M. Sousa, Mariane M.A. Stefani, Steven G. Reed

Highlights

► We produce a chimeric fusion protein incorporating selectedMycobacterium lepraeantigens. ► We demonstrate protein recognition by IgG in MB leprosy patient sera. ► We demonstrate that fusion protein stimulates IFNγ production. ► We elicit a pluripotent Ag-specific Th1 response by including a TLR4L- adjuvant. ► We show immunization inhibitsM. leprae-induced inflammation in mice.

16. **Isolation of a novel gene from *Photobacterium damselae* subsp. *piscicida* and analysis of the recombinant antigen as promising vaccine candidate** Original Research Article

Pages 820-826
Francesca Andreoni, Romina Boiani, Giordano Serafini, Giulia Amagliani, Sabrina Dominici, Giulia Riccioni, Renata Zaccone, Monique Mancuso, Giuseppe Scapigliati, Mauro Magnani

Highlights

►Reverse vaccinologyhas been used to select vaccine candidates for the treatment of fish pasteurellosis. ► A new gene of PDP for a surface-exposed lipoprotein has been identified as a vaccine candidate. ► The lipoprotein PDP_0080 is involved in the adherence of the bacterium. ► Immunization with PDP_0080 recombinant antigen conferred protection against PDP challenge. ► PDP_0080 can be a promising vaccine candidate against infection by PDP in sea bass.

17. **State law and influenza vaccination of health care personnel** Original Research Article

Pages 827-832
Alexandra M. Stewart, Marisa A. Cox

Highlights

► State laws are the most effective tool to ensure high vaccination levels among HCP. ► Nineteen states and the District of Columbia have enacted laws that require certain HCP to receive influenza vaccination. ► Laws vary in the extent to which they incorporate the elements of a model vaccination policy. ► A model law would help increase uptake of influenza vaccine among HCWs.

18. **Enhanced protective immune response to PCV2 subunit vaccine by co-administration of recombinant porcine IFN-γ in mice** Original Research Article

Pages 833-838
Yi-Ping Wang, Dan Liu, Long-Jun Guo, Qing-Hai Tang, Yan-Wu Wei, Hong-Li Wu, Jian-Bo Liu, Sheng-Bin Li, Li-Ping Huang, Chang-Ming Liu

Highlights

► Three recombinant proteins of PCV2-Cap, PoIFN-γ and Cap-PoIFN-γ were expressed. ► Three PCV2 subunit vaccines were generated based on the three recombinant proteins. ► The immunogenicity of the three PCV2 subunit vaccines was confirmed in mice. ► The PCV2-Cap+PoIFN-γ vaccine induced greater protective immunity than other vaccines. ► PoIFN-γ essentially enhanced the protective immune response to the PCV2-Cap vaccine.

19. **Relationship of influenza vaccine match and use rate to medically attended acute respiratory illnesses in older residents of Maryland. November 13, 2012** Original Research Article

Pages 839-844
James C. King, Richard Lichenstein, Laurence S. Magder

Highlights

► Retrospective CDC data revealed that influenza vaccine match to circulating influenza viruses varied from 2001 to 2008. ► Increased influenza vaccine match and use were associated with decreased respiratory illness. ► Increased proportions of A/H3N2 viruses were associated with higher rates of respiratory illness.

20. **Low opsonic activity to the infecting serotype in pediatric patients with invasive pneumococcal disease** Original Research Article

Pages 845-849
Tomohiro Oishi, Naruhiko Ishiwada, Kousaku Matsubara, Junichiro Nishi, Bin Chang, Kazuyo Tamura, Yukihiro Akeda, Toshiaki Ihara, Moon H. Nahm, Kazunori Oishi

Highlights

► IgG and OI for the infecting serotype were tested in pediatric patients with IPD. ► IgG levels were higher than 0.2μg/ml; OIs were <8 in all patients examined. ► Low opsonic activity correlates with low avidity antibodies.

21. **PER.C6® cells as a serum-free suspension cell platform for the production of high titer poliovirus: A potential low cost of goods option for world supply of inactivated poliovirus vaccine** Original Research Article

Pages 850-856
Barbara P. Sanders, Diana Edo-Matas, Jerome H.H.V. Custers, Martin H. Koldijk, Vincent Klaren, Marije Turk, Alfred Luitjens, Wilfried A.M. Bakker, Fons Uytdehaag, Jaap Goudsmit, John A. Lewis, Hanneke Schuitemaker

Highlights

► A novel cell platform is proposed for poliovirus and consequently IPV production. ► The cell-line is susceptible to all three polio virus serotypes. ► Higher yields in titers and D-antigen are attained compared to Vero cells. ► Yields can be upscaled readily from 20ml to 2L.